Scholar Rock Stock (NASDAQ:SRRK)
Previous Close
$8.59
52W Range
$5.94 - $21.17
50D Avg
$8.83
200D Avg
$13.06
Market Cap
$642.66M
Avg Vol (3M)
$819.02K
Beta
0.83
Div Yield
-
SRRK Company Profile
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Performance
Peer Comparison
Ticker | Company |
---|---|
ANAB | AnaptysBio, Inc. |
PLRX | Pliant Therapeutics, Inc. |
IDYA | IDEAYA Biosciences, Inc. |
ARVN | Arvinas, Inc. |
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. Warrant |
IKNA | Ikena Oncology, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
MGTX | MeiraGTx Holdings plc |
STOK | Stoke Therapeutics, Inc. |
CERE | Cerevel Therapeutics Holdings, Inc. |
RNA | Avidity Biosciences, Inc. |
BDTX | Black Diamond Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
BCEL | Atreca, Inc. |
IGMS | IGM Biosciences, Inc. |
PASG | Passage Bio, Inc. |
KROS | Keros Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
HOWL | Werewolf Therapeutics, Inc. |
FIXX | Q32 Bio Inc. |